Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Nora AI
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: Alligator Bioscience awarded Orphan Drug Designation for mitazalimab

Alligator Bioscience

Lund-based Alligator Bioscience continues to increase the value of its lead asset mitazalimab. The company recently announced receiving Orphan Drug Designation for the CD-40 antibody from the FDA. BioStock contacted Jonas Henningsen, VP Regulatory Affairs at Alligator, and CEO Søren Bregenholt, to learn more about what this means for the project.

Read the interview with Jonas Henningsen and Søren Bregenholt at biostock.se:

Alligator Bioscience awarded Orphan Drug Designation for mitazalimab - BioStock (https://www.biostock.se/en/2023/05/alligator-bioscience-awarded-orphan-drug-designation-for-mitazalimab/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.